Avidity Partners Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Avidity Partners Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,175,000	Closed	-$29.5M	–	101
2022 Q1	$29.5M	Buy	1,175,000 +530,600	+82%	+$14.9M	0.61%	42
2021 Q4	$23.5M	Buy	+644,400	New	+$22.6M	0.5%	54
2021 Q2	–	Sell	-940,800	Closed	-$48.2M	–	143
2021 Q1	$48.2M	Buy	940,800 +183,800	+24%	+$11.1M	1.33%	28
2020 Q4	$46.9M	Buy	+757,000	New	+$43.3M	1.52%	19
2020 Q3	–	Sell	-645,800	Closed	-$37.2M	–	96
2020 Q2	$37.2M	Buy	645,800 +409,800	+174%	+$22.3M	2.38%	12
2020 Q1	$9.48M	Buy	+236,000	New	+$10M	1.31%	30

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Avidity Partners Management's CCXI Position: Q2 2022 in Review

Avidity Partners Management sold out of ChemoCentryx, Inc. (CCXI) in Q2 2022, closing a stake of 1,175,000 shares — an estimated $29.5M sold.

Avidity Partners Management first reported a position in CCXI in Q1 2020 and held it in 6 quarters. The position peaked at $48.2M in Q1 2021. 182 funds tracked by Wall St. Rank hold CCXI as of Q2 2022.

Avidity Partners Management reported no remaining ChemoCentryx, Inc. position as of Q2 2022 after selling out during the quarter.
Avidity Partners Management sold 1,175,000 ChemoCentryx, Inc. shares in Q2 2022, an estimated $29.5M.
Avidity Partners Management first reported a position in ChemoCentryx, Inc. in Q1 2020 and held it in 6 quarters.
Avidity Partners Management's ChemoCentryx, Inc. position peaked at $48.2M in Q1 2021.
182 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2022.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.